Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Rolf Bruns"'
Autor:
Federico Amato, Rainer Strotmann, Roberto Castello, Rolf Bruns, Vishal Ghori, Andreas Johne, Karin Berghoff, Karthik Venkatakrishnan, Nadia Terranova
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 9, Pp n/a-n/a (2024)
Abstract Tepotinib is approved for the treatment of patients with non‐small‐cell lung cancer harboring MET exon 14 skipping alterations. While edema is the most prevalent adverse event (AE) and a known class effect of MET inhibitors including tep
Externí odkaz:
https://doaj.org/article/64cb53b154354915ba8eb38e3d75717f
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Duration of PFS in the patient subgroup with MET amplification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c01e965a7a4751400c9130eefc53d8
https://doi.org/10.1158/1078-0432.22820141.v1
https://doi.org/10.1158/1078-0432.22820141.v1
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Representativeness of study population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a394bfe0e9c134b3c5f2a22777c1b6
https://doi.org/10.1158/1078-0432.22820126
https://doi.org/10.1158/1078-0432.22820126
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Plain language summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::502e98744f28781160442e0abf336405
https://doi.org/10.1158/1078-0432.22665304
https://doi.org/10.1158/1078-0432.22665304
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Purpose:The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021).Patients and Methods:Adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f701c66d9574733bd03494fc801a300
https://doi.org/10.1158/1078-0432.c.6608869.v1
https://doi.org/10.1158/1078-0432.c.6608869.v1
Supplementary Figure S1. CONSORT diagram showing patient disposition.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ec48a1711e51503c427fc369e996b3
https://doi.org/10.1158/1078-0432.22455755
https://doi.org/10.1158/1078-0432.22455755
Autor:
Paul K. Paik, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Karin Berghoff, Elif Sikoglu, John Heymach, Christian Britschgi, Maya Gottfried, Melissa Johnson, Frank Griesinger, Keunchil Park, Christine M. Bestvina, Jyoti D. Patel, Yuh-Min Chen, James Chih-Hsin Yang, Hye Ryun Kim, Byoung Chul Cho, Wade T. Iams, Michael Thomas, Egbert F. Smit, Julien Mazieres, Santiago Viteri, Alexis B. Cortot, Jo Raskin, Marina Chiara Garassino, Remi Veillon, Enriqueta Felip, Hiroshi Sakai, Xiuning Le
Purpose:Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non–small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups.Patients and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5552ad5b36a619d7db55e5782ec1e34c
https://doi.org/10.1158/1078-0432.c.6531026.v1
https://doi.org/10.1158/1078-0432.c.6531026.v1
Autor:
David S. Hong, Samer El Bawab, Pascal Girard, Manja Friese-Hamim, Friedhelm Bladt, Andreas Johne, Uz Stammberger, Rolf Bruns, Manfred Klevesath, Daniel V. Catenacci, Ghazaleh Eskandari, Filip Janku, Sarina A. Piha-Paul, Siqing Fu, Wenyuan Xiong, Hesham M. Amin, Razelle Kurzrock, Gerald S. Falchook
Purpose:Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the MTD of tepotinib to determine the recommended phase II dose (RP2D).Patients and Methods:Patients received tepotinib orally accordin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671f44bbd9f87afda836e289bffa0f98
https://doi.org/10.1158/1078-0432.c.6529907
https://doi.org/10.1158/1078-0432.c.6529907
Purpose: Integrins play a critical role in the progression of prostate cancer and its bone metastases. We investigated the use of the pan-αv integrin inhibitor abituzumab in chemotherapy-naïve patients with asymptomatic or mildly symptomatic metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746f6473d1ad6b257f6dc2762df50f11
https://doi.org/10.1158/1078-0432.c.6523109
https://doi.org/10.1158/1078-0432.c.6523109
Autor:
David S. Hong, Samer El Bawab, Pascal Girard, Manja Friese-Hamim, Friedhelm Bladt, Andreas Johne, Uz Stammberger, Rolf Bruns, Manfred Klevesath, Daniel V. Catenacci, Ghazaleh Eskandari, Filip Janku, Sarina A. Piha-Paul, Siqing Fu, Wenyuan Xiong, Hesham M. Amin, Razelle Kurzrock, Gerald S. Falchook
Supplementary information showing details of study criteria, bioasssays, preclinical modelling, PK data, safety and efficacy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7690cb145a7b5a77f8a21817acc152e7
https://doi.org/10.1158/1078-0432.22478273
https://doi.org/10.1158/1078-0432.22478273